Evogene Ltd.
corporate_fare Company Profile
Evogene Ltd. (NASDAQ:EVGN) is a publicly traded company in the Industrial Applications And Services sector. Wiseek monitors EVGN SEC EDGAR filings and licensed market news in real time, scoring each submission for market-moving significance on a 1–10 scale. Items rated 7 or higher generate instant alerts.
Recent high-impact activity:
- Activist Group Rejects Settlement, Raises Stake to 17.41%, and Sets July 31 Deadline for Board Overhaul
- Evogene Partners with ELEO to Develop Oral PCSK9 Inhibitors for $23B Cardiovascular Market
- Activist Group Raises Stake to 16.81% with $120K in New Purchases Amid Proxy Fight
- Evogene Upsizes ATM to $3.3M, Reveals $1.75M Already Sold Amid Proxy Fight
- Evogene Upsizes ATM to $3.3M and Flags Activist Proxy Fight Risks
Financial Snapshot
Dilution Risk
Low riskFiling-implied dilution signals for EVGN, detected from its recent SEC filings · based on capital-structure filings through 2026-07-17.
ATM Upsized to $3.3M · $1.75M Already Sold
⚠ A more recent filing has been published for this ticker since this signal was computed; it may not yet be reflected — see the filings below.
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →
Insider Transactions
EVGN files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.